Abstract 4368317: Identifying cardioprotective strategies against DOX-induced cardiotoxicity using mature, mitochondrial-rich and patient-derived hiPSC-cardiomyocytes

Introduction: Doxorubicin (DOX) is widely used in cancer treatment but may cause mitochondrial damage and cardiotoxicity. Dexrazoxane is the only clinically approved intervention for DOX-induced cardiotoxicity (DCT); however, it may reduce DOX's anti-cancer effectiveness. The discovery of new drugs is hampered by the lack of appropriate human models and the challenge of balancing cardioprotection with cancer management. Aims: We aim to establish a clinically relevant model of DCT and identify novel treatment. Methods: We previously identified CD36 as a surface marker of CM maturation. Human pluripotent stem cell derived (hPSC)-cardiomyocytes (CMs) with high CD36 (CD36 hi CM) have more mitochondria. They also recapitulate the protective effects of dexrazoxane against DCT, unlike immature, conventional hiPSC-CM cultures. Here, we established a clinically relevant model of DCT using patient-derived hiPSC-CD36hi CMs. Using this model, we performed a targeted screen to identify compounds that can supress DCT. Selected candidates were further tested for their effects on a panel of cancer cells. Cardioprotective effects were then validated in mouse in vivo models. Results: Patient-derived CD36 hi hiPSC-CMs had more mitochondria and better mitochondrial function relative to CD36 lo CMs, and recapitulated the protective effects of dexrazoxane against DCT. Using this model, we identified drug candidates that can protect the mitochondria and increase CM viability. Further screening revealed a subset of candidates that do not affect or even suppress the viability of cancer cells. Echocardiography and histopathological examinations confirmed cardioprotection in vivo. Conclusion: Patient-derived CD36 hi CMs is critical for the identification of new treatment against DCT. Using this and an in vivo model, we identified candidates that suppress DCT without protecting or even suppress cancer.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2025-11-03
DOI
https://doi.org/10.1161/circ.152.suppl_3.4368317
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4368317: Identifying cardioprotective strategies against DOX-induced cardiotoxicity using mature, mitochondrial-rich and patient-derived hiPSC-cardiomyocytes

Ellen Poon, Maxwell Kwok, C. Chen, Binbin Wu et al.
Circulation
Chemotherapy-induced cardiotoxicity and mitigation
article

Abstract 4368317: Identifying cardioprotective strategies against DOX-induced cardiotoxicity using mature, mitochondrial-rich and patient-derived hiPSC-cardiomyocytes

Ellen Poon, Maxwell Kwok, C. Chen, Binbin Wu, Chloe Ma
article en

Abstract

Introduction: Doxorubicin (DOX) is widely used in cancer treatment but may cause mitochondrial damage and cardiotoxicity. Dexrazoxane is the only clinically approved intervention for DOX-induced cardiotoxicity (DCT); however, it may reduce DOX's anti-cancer effectiveness. The discovery of new drugs is hampered by the lack of appropriate human models and the challenge of balancing cardioprotection with cancer management. Aims: We aim to establish a clinically relevant model of DCT and identify novel treatment. Methods: We previously identified CD36 as a surface marker of CM maturation. Human pluripotent stem cell derived (hPSC)-cardiomyocytes (CMs) with high CD36 (CD36 hi CM) have more mitochondria. They also recapitulate the protective effects of dexrazoxane against DCT, unlike immature, conventional hiPSC-CM cultures. Here, we established a clinically relevant model of DCT using patient-derived hiPSC-CD36hi CMs. Using this model, we performed a targeted screen to identify compounds that can supress DCT. Selected candidates were further tested for their effects on a panel of cancer cells. Cardioprotective effects were then validated in mouse in vivo models. Results: Patient-derived CD36 hi hiPSC-CMs had more mitochondria and better mitochondrial function relative to CD36 lo CMs, and recapitulated the protective effects of dexrazoxane against DCT. Using this model, we identified drug candidates that can protect the mitochondria and increase CM viability. Further screening revealed a subset of candidates that do not affect or even suppress the viability of cancer cells. Echocardiography and histopathological examinations confirmed cardioprotection in vivo. Conclusion: Patient-derived CD36 hi CMs is critical for the identification of new treatment against DCT. Using this and an in vivo model, we identified candidates that suppress DCT without protecting or even suppress cancer.

CirculationVol. 152(Suppl_3)
Chinese University of Hong Kong (HK)
Openalex Percentile: Top 52%
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.